Genentech, Inc.

Biogen Idec Ma Inc.

F. Hoffmann-la Roche Ag

Flavius Martin

Michael Townsend

Glynn Dennis, Jr

Tatiana Novobrantseva

Yen-Ming Hsu

Susan L Kalled

Andrew C Chan

Leonid Gorelik

Andrew Chee-Yuen Chan

Qian Gong

Joanne Quan

Michael J Townsend

Glynn Dennis

Methods of identifying, diagnosing, and prognosing rheumatoid arthritis are provided, as well as methods of treating rheumatoid arthritis. Also provided are methods for identifying effective rheumatoid arthritis therapeutic agents and predicting responsiveness to rheumatoid arthritis therapeutic agents.

Methods for treating, diagnosing, and monitoring rheumatoid arthritis

The present invention relates to novel methods for treating diseases and monitoring B cell levels in subjects and kit and compositions relating thereto by measuring serum BAFF levels in the subjects.

Methods and compositions related to B cell assays

BAFF plays a central role in acquired immunity. The disclosure identifies BAFF-responsive genes that are substantially upregulated by administration of BAFF and substantially downregulated by treatment with a BAFF antagonist. Specific genes are: NF-&#x3ba;B2, CD23, H2-M&#x3b2; (the beta chain of H2-DM), Fig-1, and OBF-1. The disclosure provides methods and compositions for: monitoring the activity of a BAFF antagonist in a mammal; monitoring BAFF activity in a mammal; identifying a mammal to be treated with a BAFF antagonist; and related uses. Such methods include detecting one or more molecules selected from the group consisting of Fig-1 molecule, OBF-1 molecule, and H2-M&#x3b2; molecule in a biological sample of the mammal, and optionally further detecting NF-&#x3ba;B2 molecule and/or CD23 molecule in the biological sample.

Methods for use with BAFF antagonists

The invention provides anti-OX40L antibodies, and compositions comprising and methods of using these antibodies.

Anti-OX40L antibodies and methods using same

The present invention generally relates to non-human transgenic animals expressing human cellular markers, including CD20 and/or preferably CD16.

Transgenic mice expressing human CD20 and/or CD16

Growing community of inventors

Hayward, CA, United States of America

Flavius Martin